Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 500 mg Metformin Immediate Release (IR) Tablet Relative to 2.5 mg Saxagliptin Tablet and 500 mg Metformin IR Tablet Co-Administered to Healthy Subjects in a Fasted and in a Fed State

Trial Profile

Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 500 mg Metformin Immediate Release (IR) Tablet Relative to 2.5 mg Saxagliptin Tablet and 500 mg Metformin IR Tablet Co-Administered to Healthy Subjects in a Fasted and in a Fed State

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2014

At a glance

  • Drugs Saxagliptin/metformin (Primary) ; Metformin; Saxagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 23 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jun 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 19 Jun 2009 Location USA identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top